Gregory Lesinski
@LesinskiLab
Followers
2K
Following
10K
Media
149
Statuses
1K
The Lesinski Laboratory is focused on understanding the interactions between the immune system and cancer. opinions are my own. #immunotherapy #GICancer
Georgia, USA
Joined November 2016
Exciting new #tcell #celltherapy publication led by @megen_wittling and @hknochelmann from @Chrystal_Paulos @PaulosLab @WinshipAtEmory Grateful to contribute to discoveries of this stellar team. @CIR_AACR
🚨Our new study (@megen_wittling et. al.) shows how neoantigen avidity rewires T cell fate and determines ACT success🚨 High-avidity antigen→rapid LN priming, strong effector function, durable tumor control. Low-avidity→stalled T cells & therapy failure. https://t.co/RAYhSkN49B
0
3
6
https://t.co/CeBube0AhQ Long awaited ms @CR_AACR on pri/mets #PDAC! Many year effort @WinshipAtEmory led by #emilygreene and @natalie_horvat with collabs @cameron_herting @Egrunds @AyanaTRuffin @skmaithel @MihirMShah1 @MariaDiab101 @olatunji @HaydnKissick @Chrystal_Paulos +more
3
22
114
Excited to welcome the brilliant @PoHienEar to @WinshipAtEmory !!
I’m thrilled to announce that I will be joining @WinshipAtEmory in Feb 2026! Many thanks to everyone for all your support! 🙏 Looking forward to expanding our neuroendocrine cancer program to better serve the NET community! @CureNETs @NANETS1 @ENETS_ORG @netcancerfound
1
4
18
Amplifying a rare cancer and opportunity to support those like @MarkYarchoan working on it!
Ethan Neumann, a 27-year-old PhD candidate in my lab, devoted himself to studying #fibrolamellar carcinoma, the cancer that claimed his life last week. Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️ https://t.co/g4orF0msmb
0
0
5
I’m pleased to share that registration for the CCF Annual Conference is now open! Join us May 1–3 in Salt Lake City. Patients can apply for a scholarship during the registration process. Don’t miss this chance to connect, learn, and share. Register: https://t.co/f0MgeQOnPc.
1
4
10
So grateful to @PAscierto for opportunity to present at the 2025 Bridge meeting in the amazing city of Napoli! @BernardAFox was the guru at cataloging meeting highlights! Catching up with old friends, exploring ruins with @Chrystal_Paulos and amazing food! Best meeting ever!
1
1
8
Congrats to this awesome team @HopkinsMedicine @MarkYarchoan on a major advance in a very rough disease!
https://t.co/73POdY5OoK Full paper:
0
0
7
The 2025 @WinshipAtEmory Scientific Symposium is focused on AI and Big Data. Keynote by @anantm. @EmoryUniversity @AdamMarcusPhD @theNCI
0
4
19
💥 Cheers to Dr. Anna Cole @AnnaCamille98. Excited to celebrate Anna today at her public defense on the novel role of adoptive T cell therapy on triggering humoral immunity against established tumors. @WinshipAtEmory @CancerBioEmory 💥
0
4
35
Amazing day at the @WinshipAtEmory annual 5K! Consider donating to cancer research at the following link. All gifts large or small are appreciated! https://t.co/lhCujXTDnO
secure2.convio.net
Gregory Lesinski Winship 5K Page
0
0
6
More exciting work in the Kras targeting arsenal from @Aiims1742 @KalluriLab and more
An experimental pan-KRAS inhibitor reprograms the tumor microenvironment in #PDAC and potentiates T cell infiltration, and suppresses cancer growth in mouse models while sensitizing tumors to checkpoint blockade. @Aiims1742 @KalluriLab @mcandrews_kate
https://t.co/wOsZcVAUX6
3
1
18
New #JITC position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies https://t.co/KEppHD6J1h
@StefanieBailey_ @ScienceKyle @ChrisHeery
@LesinskiLab @megen_wittling @Chrystal_Paulos @PaulosLab
3
9
26
🚨New in @JITCancer! Thrilled to share our position article, co-led w/Dr. Posey @IAmDrDex, on engineering next wave of antibody & cell therapies. Let’s build the future of immuno-oncology.🧵 #NextGenIO @PennMedicine @WinshipAtEmory @sitcancer 🔗
jitc.bmj.com
Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in...
4
14
56
Very lucky to work with these all stars!
Honored to be awarded the All-Star V Foundation grant! Inspired by great team efforts between @PaulosLab @LesinskiLab! Props to cell therapy gurus @megen_wittling @AnnaCamille98 #MeganWyatt @WinshipAtEmory!
0
0
9
Congrats to our collaborators @PaulosLab @Chrystal_Paulos @AnnaCamille98 @hknochelmann @WinshipAtEmory on this tremendous @Cancer_Cell work! Comprehensive tweetorial below. Punchline: Th17 therapy needs the B cells! #Tcell #immunotherapy #Bcell
BREAKING: We uncovered a potent immune alliance that could change how we treat solid tumors. Published in @Cancer_Cell , we show that Th17 cells *must* work with B cells to eliminate tumors—and keep it from coming back. 📄 https://t.co/C6WMHRHMM5 🧵1/12👇Let’s walk through it:
1
2
21
High impact report from @Zihai with many other superb @OSUCCC_James colleagues @CarsonLabOSU and more on #nkcell and #tcell interactions. Check it out!!
Are #NK_cells friends or foes in cancer #immunotherapy? We found they impede the development of anti-tumor NK-regulated T cells (#NKRTs). https://t.co/fDvCvLriwA A separate study by @lab_marine showed that NK cells contribute to ICB resistance in melanoma. https://t.co/T4Vx3iBXek
0
0
10
Check out our new paper in Hepatology on how myeloid cells limit #immunotherapy in preclinical #cholangiocarcinoma models! Disease site matters! Collaborative effort with @Chrystal_Paulos and many others @WinshipAtEmory @KimmelCancerCtr @VanderbiltU
https://t.co/Ug08v6zKlo
pubmed.ncbi.nlm.nih.gov
These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant...
2
10
24
Cool pre-print alert! @Chrystal_Paulos @megen_wittling @PaulosLab @WinshipAtEmory offer new insight into how neoAg help adoptively transferred #Tcells traffic!
Checkout our teams new work by @megen_wittling et. al. @WinshipAtEmory on how neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking | bioRxiv
0
0
10